

---

# Contents

---

<i>Preface</i>	<i>v</i>
<i>Contributors</i>	<i>vii</i>

## Section One. Principles of Chemotherapy

### Scientific Foundation of Chemotherapy

#### Routes of Administration

<b>1/ The Scientific Basis of Cancer Chemotherapy</b> John W. Yarbro, M.D., Ph.D.	2
<b>2/ Antineoplastic Drug Development</b> Barbara A. Conley, M.D. David A. Van Echo, M.D.	15
<b>3/ Principles of Pharmacology and Pharmacokinetics</b> Mark J. Ratain, M.D. Richard L. Schilsky, M.D.	22
<b>4/ The Norton-Simon Hypothesis</b> Larry Norton, M.D.	36
<b>5/ Drug Resistance</b> James H. Goldie, M.D., S.R.C.P.C.	54
<b>6/ Adjuvant Chemotherapy</b> Teresa Gilewski, M.D. Jacob D. Bitran, M.D.	67
<b>7/ Combination Chemotherapy</b> Michael L. Friedland, M.D.	90
<b>8/ Hematopoietic Growth Factors</b> Marc B. Garnick, M.D.	96
<b>9/ Combined Modality Therapy</b> Eric L. Raefsky, M.D. Todd H. Wasserman, M.D.	110
<b>10/ The Design and Interpretation of Clinical Trials</b> Richard Simon, Ph.D. Michael A. Friedman, M.D.	130

<b>11/ Biologic Response Modifiers: Principles of Immunotherapy</b>	144
Susan A. Melin, M.D.	
Howard Ozer, M.D., Ph.D.	
<b>12/ Chemotherapy: Circadian Timing and Toxicity</b>	165
William J.M. Hrushesky, M.D.	
<b>13/ Intraventricular Therapy</b>	213
Arthur D. Forman, M.D.	
Victor A. Levin, M.D.	
<b>14/ Intraperitoneal Chemotherapy</b>	226
Maurie Markman, M.D.	
<b>15/ Continuous Intravenous Infusion Chemotherapy</b>	232
Robert W. Carlson, M.D.	
<b>16/ Intraarterial Therapy</b>	256
William D. Ensminger, M.D., Ph.D.	
<b>17/ Perfusion Therapy</b>	272
William G. Kraybill, M.D.	
<b>18/ Bone Marrow Transplantation</b>	280
Julie M. Vose, M.D.	
James O. Armitage, M.D.	

## **Section Two. Chemotherapeutic Drugs**

<b>19/ Alkylating Agents</b>	286
Gerald H. Clamon, M.D.	
<b>20/ Antimetabolites</b>	301
Richard L. Schilsky, M.D.	
<b>21/ Antitumor Antibiotics and Related Compounds</b>	318
Charles E. Riggs, Jr., M.D.	
<b>22/ Vinca Alkaloids and Epipodophyllotoxins</b>	359
Eric K. Rowinsky, M.D., F.A.C.P.	
Ross C. Donehower, M.D., F.A.C.P.	
<b>23/ Nitrosoureas</b>	384
Edith P. Mitchell, M.D.	
Philip S. Schein, M.D.	
<b>24/ Enzymes and Random Synthetics</b>	398
Alan P. Lyss, M.D.	
<b>25/ Hormonal Agents</b>	413
Joseph Aisner, M.D.	
Mario A. Eisenberger, M.D.	
Joseph A. Fontana, M.D.	

<b>26/ Biologics</b>	<b>430</b>
Edward T. Creagan, M.D.	
<b>27/ Investigational Drugs</b>	<b>439</b>
Daniel R. Budman, M.D., F.A.C.P.	
 <b>Section Three. Management of Drug Toxicity</b>	
<b>28/ Hematologic Complications of Cancer Chemotherapy</b>	<b>498</b>
H. Clark Hoagland, M.D., F.A.C.P.	
<b>29/ Oral Toxicity</b>	<b>508</b>
Douglas E. Peterson, D.M.D., Ph.D.	
Mark M. Schubert, D.D.S., M.S.D.	
<b>30/ Dermatologic Toxicity</b>	<b>531</b>
John D. DeSpain, M.D.	
<b>31/ Extravasation</b>	<b>548</b>
Gerald H. Clamon, M.D.	
<b>32/ Hypersensitivity Reactions</b>	<b>553</b>
Raymond B. Weiss, M.D.	
<b>33/ Ocular Side Effects of Chemotherapy</b>	<b>570</b>
Linda J. Burns, M.D.	
<b>34/ The Cardiotoxicity of Chemotherapeutic Drugs</b>	<b>582</b>
Ace Allen, M.D.	
<b>35/ Pulmonary Toxicity of Antineoplastic Therapy</b>	<b>598</b>
Harvey Kreisman, M.D.	
Norman Wolkove, M.D.	
<b>36/ Gastrointestinal Toxicity of Chemotherapeutic Agents</b>	<b>620</b>
Edith P. Mitchell, M.D.	
Philip S. Schein, M.D.	
<b>37/ Hepatotoxicity of Chemotherapeutic Agents</b>	<b>635</b>
Michael C. Perry, M.D., F.A.C.P.	
<b>38/ Renal and Electrolyte Abnormalities Due to Chemotherapy</b>	<b>648</b>
William P. Patterson, M.D.	
Garry P. Reams, M.D.	
<b>39/ Neurotoxicity of Chemotherapeutic Agents</b>	<b>666</b>
David R. MacDonald, M.D., F.R.C.P.C.	
<b>40/ Vascular Toxicity</b>	<b>680</b>
Q. Scott Ringenberg, M.D.	
<b>41/ Second Malignancies After Chemotherapy</b>	<b>689</b>
Robert A. Kyle, M.D., F.A.C.P.	
Morie A. Gertz, M.D.	

<b>42/ Chemotherapy in Pregnancy</b>	703
Donald C. Doll, M.D.	
<b>43/ Gonadal Toxicity and Teratogenicity</b>	710
Ramona M. Chapman, M.D.	

## **Section Four. Combination Chemotherapy Programs**

<b>44/ Combination Chemotherapy Programs</b>	756
Michael C. Perry, M.D., F.A.C.P.	

## **Section Five. Drug Administration**

<b>45/ Central Venous Access for Chemotherapy</b>	780
Marvin J. Lopez, M.D.	
<b>46/ Safe Handling of Cytotoxic Drugs: A Review</b>	799
Bruce R. Harrison, M.S., R.Ph.	
<b>47/ Stability and Compatibility of Intravenous Oncology Drugs</b>	833
(Modified from Cetus Corporation)	
<b>48/ Patient Education</b>	853
Mary H. Johnson, M.S.N., R.N., O.C.N.	
Verna A. Rhodes, Ed.S., R.N.	
<b>49/ Nursing Implications in the Administration of Cancer Chemotherapy</b>	873
Connie Henke Yarbro, R.N., B.S.N.	

## **Section Six. Current Therapy of Specific Tumors**

<b>50/ Chemotherapy of Melanoma</b>	886
Michael J. Mastrangelo, M.D.	
Robert E. Bellet, M.D.	
Michael J. Kane, M.D.	
David Berd, M.D.	
<b>51/ Chemotherapy of Primary Brain Tumors</b>	908
Roy A. Patchell, M.D.	
<b>52/ Head and Neck Cancer</b>	918
Everett E. Vokes, M.D.	
<b>53/ Chemotherapy of Lung Cancer</b>	932
Vicki A. Morrison, M.D.	
Sharon D. Luikart, M.D.	
<b>54/ Chemotherapy of Breast Cancer</b>	948
Carl G. Kardinal, M.D., F.A.C.P.	
<b>55/ Chemotherapy of Gastrointestinal Cancer</b>	989
Michael C. Perry, M.D., F.A.C.P.	

<b>56/ Chemotherapy of Endocrine Tumors</b>	<b>998</b>
Ronald L. Stephens, M.D.	
<b>57/ Chemotherapy of Genitourinary Cancer</b>	<b>1008</b>
Nicholas J. Vogelzang, M.D.	
<b>58/ Chemotherapy of Gynecologic Cancer</b>	<b>1039</b>
J. Tate Thigpen, M.D.	
<b>59/ Sarcomas of Bone and Soft Tissue</b>	<b>1068</b>
Karen H. Antman, M.D.	
<b>60/ Chemotherapy of Hematologic Malignancies</b>	
<i>Part 1. Leukemias and Lymphomas</i>	1094
James K. Weick, M.D.	
<i>Part 2. The Treatment of Multiple Myeloma and Related Plasma Cell Dyscrasias</i>	1110
Medhi Farhangi, M.D., F.A.C.P.	
Ali Khojasteh, M.D., F.A.C.P.	
<b>61/ Pediatric Solid Tumors</b>	<b>1122</b>
Nasrollah Hakami, M.D.	
<b>Appendix/ WHO Toxicity Guidelines</b>	<b>1132</b>
Michael C. Perry, M.D., F.A.C.P.	
<b>Index</b>	<b>1145</b>

